NRXS Share Price Performance
US$2.70
0.13 (5.06%)
10.0% undervalued intrinsic discount
US$3.00
Fair Value
Price US$2.70
AnalystLowTarget US$3.00
Fair ValueUS$3.00
Share Pricen/a
NeurAxis, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
NRXS Community Narratives
AN
Fair Value US$3 10.0% undervalued intrinsic discount
New CPT Code And Adult Trial Risks Will Challenge Neuromodulation Outlook Yet Offer Some Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
New CPT Code And Adult Trial Risks Will Challenge Neuromodulation Outlook Yet Offer Some Promise
Catalysts About NeurAxis NeurAxis develops neuromodulation devices such as IB-Stim and RED to treat functional gastrointestinal disorders in pediatric and adult populations. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$3
10.0% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
103.58% p.a.
Profit Margin
0.13%
Future PE
13.15x
Price in 2028
US$0.02
Trending Discussion
Recently Updated Narratives
AN
New CPT Code And Adult Trial Risks Will Challenge Neuromodulation Outlook Yet Offer Some Promise
Fair Value: US$3 10.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NeurAxis, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.78
- 84.35%
- -247.63%
- 9.4%
About NRXS
- Founded
- 2011
- Employees
- 21
- CEO
- WebsiteView website
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
